A/S (Nasdaq: ASND) today announced that YORVIPATH® (palopegteriparatide; developed as TransCon PTH) is now commercially ...

Expert Rev Endocrinol Metab. 2012;7(3):255-257. The future of hormone replacement therapy in hypoparathyroidism can be viewed with optimism, even if we are left with several unanswered questions ...

After turning it down a year ago, the FDA has cleared once-daily injectable Yorvipath for hypoparathyroidism from Ascendis Pharma. Yorvipath (palopegteriparatide) – previously known as TransCon ...

It is the first and only medicine approved by the U.S. Food & Drug Administration (FDA) for the treatment of hypoparathyroidism in adults. "Members of our community have shared so many stories of ...

Considering taking supplements to treat hypoparathyroidism? Below is a list of common natural remedies used to treat or reduce the symptoms of hypoparathyroidism. Follow the links to read common ...

Analysts foresee potential from SEP-786 for hypoparathyroidism, with Phase 1 data expected in mid-2025. A couple of analysts initiated coverage on Septerna, Inc. SEPN, which debuted on NASDAQ last ...

Er-Kim has extended its exclusive agreement with Ascendis Pharma, broadening the reach of three endocrinology treatments ...

Septerna (), which is developing a treatment for hypoparathyroidism, has proposed terms for an upsized $175M initial public ...